Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | PYGM | P11217 | 1/20 | 0.31 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | HTR2A | P28223 | 1/20 | 0.30 |
| ▸ | HRH1 | P35367 | 1/20 | 0.30 |
| ▸ | SCN1A | P35498 | 1/20 | 0.30 |
| ▸ | SCN4A | P35499 | 1/20 | 0.30 |
| ▸ | BLM | P54132 | 1/20 | 0.30 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.30 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.30 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.30 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.30 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.30 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.30 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.30 |
| ▸ | MMP2 | P08253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6696060 | 0.78 | LMNA (0.32) | LMNACACNA1FALDH1A1MAPTCYP2C9 | |
| SCHEMBL11818576 | 0.70 | LMNA (0.39) | LMNAMMP2MMP9 | |
| SCHEMBL5197417 | 0.70 | CYP2C9 (0.35) | PYGMCACNA1FALDH1A1MAPTCYP2C9 | |
| SCHEMBL753785 | 0.64 | ITGA4 (0.37) | LMNACACNA1FALDH1A1MAPTCYP2C9 | |
| SCHEMBL21196916 | 0.64 | — | — | |
| SCHEMBL12803697 | 0.64 | LMNA (0.36) | LMNACACNA1FALDH1A1MAPTCYP2C9 | |
| SCHEMBL6278824 | 0.64 | LMNA (0.36) | LMNACACNA1FALDH1A1MAPTCYP2C9 | |
| SCHEMBL1363411 | 0.62 | — | — | |
| SCHEMBL20153077 | 0.62 | — | — | |
| SCHEMBL8225316 | 0.62 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100292321-A1 | BIOFILM CONTROL | ALBEMARLE CORPORATION (US) | 2010-11-18 | — | — | US | disclosed |
| EP-2034837-A1 | BIOFILM CONTROL | Albermarle Corporation (US) | 2009-03-18 | — | — | EP | disclosed |
| WO-2008003085-A1 | BIOFILM CONTROL | ALBEMARLE CORPORATION (US) | 2008-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292321-A1 | BIOFILM CONTROL | CD47, MLEC, EPCAM | LMNA 3240/4885PYGM 3547/4885CACNA1F 3813/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.